Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Par Pharmaceutical Companies Inc.

http://www.parpharm.com

Latest From Par Pharmaceutical Companies Inc.

Finance Watch: Two New VC Funds Raise $755m To Fund Innovation

Private Company Edition: Also, Medicxi’s new €200m fund will be reinvested in a portfolio of six life science companies and Silverback more than doubled its 2020 money with an $85m series C round.

Financing StartUps and SMEs

Endo’s Par Competes With Amneal On Sucralfate

Endo’s Par has partnered with Allergan to launch an authorized generic of Carafate sucralfate oral suspension in the US, competing directly with the first generic version recently launched by Amneal.

Launches Generic Drugs

HanAll Advancing Novel Dry Eye Contender Despite Mixed Top-Line

HanAll and Daewoong remain upbeat on dry eye candidate HL036 and are gearing up for a second Phase III US study despite the first missing its primary endpoint in just-released top-line results.

Ophthalmic Clinical Trials

Momentum Is Back At Cipla In Q2

Cipla had a strong run across key businesses in Q2, with products like generic Sensipar retaining share in the US despite stiff competition. But launch timelines for generic albuterol in the US have been pushed back to fiscal 2021.

Sales & Earnings Companies
See All

Company Information

  • Other Names / Subsidiaries
    • Anchen Pharmaceuticals, Inc.
    • Edict Pharmaceuticals Private Limited
    • JHP Pharmaceuticals, LLC
    • Strativa Pharmaceuticals
    • TPG Capital LP
UsernamePublicRestriction

Register